PROVECTUS BIOPHARMACEUTICALS, INC.
Data quality: 100%
PVCT
OTC
Manufacturing
Chemicals
$0.05
▼
$0.01
(-12.28%)
Mkt Cap: 21.01 M
Price
$0.05
Mkt Cap
21.01 M
Day Range
$0.05 — $0.06
52-Week Range
$0.04 — $0.11
Volume
25,200
Open $0.06
50D / 200D Avg
$0.05
0.99% below
50D / 200D Avg
$0.07
25.26% below
Quick Summary
Key Takeaways
Negative free cash flow of -3.33 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)-45.54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROICN/A
Net Margin-1615.81%
Op. Margin-1575.32%
Safety
Debt / Equity
N/A
Current Ratio0.04
Interest Coverage-991.90
Valuation
PE (TTM)
-3.87
Below sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -3.9 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.5 |
| Net Margin % | -1615.8 | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -45.54% | Revenue Growth (3Y) | -22.37% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 336,108.0 | Net Income (TTM) | -5.43 M |
| ROE | N/A | ROA | -950.87% |
| Gross Margin | N/A | Operating Margin | -1575.32% |
| Net Margin | -1615.81% | Free Cash Flow (TTM) | -3.33 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0.04 |
| Interest Coverage | -991.90 | Asset Turnover | 0.59 |
| Working Capital | -6.19 M | Tangible Book Value | -6.15 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3.87 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 62.52 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -15.83% | ||
| Market Cap | 21.01 M | Enterprise Value | 20.94 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.01 | Revenue / Share | 0.00 |
| FCF / Share | -0.01 | OCF / Share | -0.01 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 61.24% |
| SBC-Adj. FCF | -4.28 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 336,108.0 | 617,140.0 | 557,710.0 | 989,042.0 | — |
| Net Income | -5.43 M | -4.73 M | -3.10 M | -3.55 M | -5.54 M |
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -5.29 M | -4.53 M | -2.90 M | -3.43 M | -4.67 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 1.90 M | 2.00 M | 1.75 M | 2.39 M | 2.61 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 5,338.0 | 13,591.0 | 5,650.0 | -163,691.0 | 961,702.0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 697,502.0 | 1.01 M | 1.45 M | 2.04 M | 3.51 M |
| Total Liabilities | 7.00 M | 6.98 M | 9.04 M | 8.27 M | 7.70 M |
| Shareholders' Equity | -6.30 M | -5.96 M | -7.59 M | -6.23 M | -4.19 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 251,291.0 | 307,442.0 | 76,576.0 | 21,605.0 | 682,984.0 |
| Current Assets | 567,874.0 | 976,772.0 | 1.36 M | 1.90 M | 3.44 M |
| Current Liabilities | 6.90 M | 6.98 M | 9.02 M | 8.19 M | 7.70 M |
{"event":"ticker_viewed","properties":{"ticker":"PVCT","listing_kind":"stock","pathname":"/stocks/pvct","exchange":"OTC","country":"US"}}